SCHEMBL4090912

SCHEMBL4090912

Cc1ccc(-c2ccc(Br)s2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
HSD17B10 Q99714 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALOX12 P18054 2/20 0.44
ALOX15 P16050 1/20 0.44
KDM4E B2RXH2 5/20 0.42
RXFP1 Q9HBX9 4/20 0.42
LMNA P02545 3/20 0.42
POLB P06746 3/20 0.42
PPARG P37231 2/20 0.42
NCOA2 Q15596 2/20 0.42
NPC1 O15118 5/20 0.42
ALDH1A1 P00352 4/20 0.42
GFER P55789 1/20 0.42
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 2/20 0.41
HPGD P15428 2/20 0.41
NCOA1 Q15788 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8508163 0.98 MAPT (0.42) MAPTHSD17B10MEN1KMT2AALOX12
SCHEMBL131605 0.84
SCHEMBL29764 0.84 NPC1 (0.52) MAPTHSD17B10MEN1KMT2AALOX15
SCHEMBL197157 0.84 SNCA (0.50) MAPTHSD17B10MEN1KMT2AALOX12
SCHEMBL14125018 0.83 MAPT (0.37) MAPTHSD17B10MEN1KMT2AALOX12
SCHEMBL12170048 0.81 NPC1 (0.50) MAPTHSD17B10MEN1KMT2AALOX15
SCHEMBL5889177 0.81 SNCA (0.48) MAPTHSD17B10MEN1KMT2AALOX12
SCHEMBL12982405 0.81 NPC1 (0.50) MAPTHSD17B10MEN1KMT2AALOX15
SCHEMBL120939 0.81 NPC1 (0.50) MAPTHSD17B10MEN1KMT2AALOX15
SCHEMBL5453288 0.81 SNCA (0.48) MAPTHSD17B10MEN1KMT2AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964704-B1 HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF BASF SE (DE) 2018-05-16 EP disclosed
US-9893302-B2 Heterocyclic fluorescent dyes and method of production thereof BASF SE (DE) 2018-02-13 US disclosed
US-20170133606-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF CLAP CO., LTD. (KR) 2017-05-11 US disclosed
US-20170133606-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF CLAP CO., LTD. (KR) 2017-05-11 US disclosed
US-9595680-B2 Heterocyclic fluorescent dyes and method of production thereof BASF SE (DE) 2017-03-14 US disclosed
US-9595680-B2 Heterocyclic fluorescent dyes and method of production thereof BASF SE (DE) 2017-03-14 US disclosed
US-9328127-B2 System for controlling the reactivity of boronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-05-03 US disclosed
US-20150380660-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF BASF SE (DE) 2015-12-31 US disclosed
US-20150380660-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF BASF SE (DE) 2015-12-31 US disclosed
WO-2014135491-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF BASF SE (DE) 2014-09-12 WO disclosed
WO-2010107784-A1 METHODS FOR ACTIVATION CONTROL OF PHOTOPOLYMERIZATION FOR HOLOGRAPHIC DATA STORAGE USING AT LEAST TWO WAVELENGTHS STX APRILIS, INC. (US) 2010-09-23 WO disclosed
US-20090069384-A1 THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2009-03-12 US disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1844051-A1 THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-10-17 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
WO-2007009690-A1 HETEROCYCLYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A (ES) 2007-01-25 WO disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed
WO-2006077412-A1 THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150380660-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF ORAI3, SLCO1B3, SLCO4C1 MAPT 2456/4885HSD17B10 1227/4885MEN1 1137/4885
US-20090069384-A1 THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION NPY5R, TH, PTGES MAPT 54/4885HSD17B10 3431/4885MEN1 3153/4885
US-20170133606-A1 NOVEL HETEROCYCLIC FLUORESCENT DYES AND METHOD OF PRODUCTION THEREOF ORAI3, SLCO1B3, SLCO4C1 MAPT 2456/4885HSD17B10 1227/4885MEN1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.